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Why do physicians lack engagement with smoking cessation
treatment in their COPD patients? A multinational qualitative
study
Eva Anne Marije van Eerd1, Mette Bech Risør2, Mark Spigt1,2, Maciek Godycki-Cwirko3, Elena Andreeva4, Nick Francis5, Anja Wollny6,
Hasse Melbye2, Onno van Schayck1 and Daniel Kotz1,7
Smoking cessation is the only effective intervention to slow down the accelerated decline in lung function in smokers with chronic
obstructive pulmonary disease. Nevertheless, physicians often do not routinely provide evidence-based smoking cessation
treatment to their patients. To understand underlying reasons, we explored how physicians engage in smoking cessation treatment
in their chronic obstructive pulmonary disease patients. In total, 21 focus group discussions were held with general practitioners
and pulmonologists in seven different countries in Europe and Asia. We generated three themes, whereby some of the issues
concerned smokers in general: ﬁrst, ‘physicians’ frustration with chronic obstructive pulmonary disease patients who smoke’. These
frustrations interfered with the provision of evidence-based treatment and could result in this group of patients being treated
unequally. Second: ‘physicians’ limited knowledge of, and negative beliefs about, smoking cessation treatment’. This hindered
treating smokers effectively. Third: ‘healthcare organisational factors that inﬂuence the use of smoking cessation treatments’.
Money and time issues, as well as the failure to regard smoking as a disease, inﬂuenced how physicians engaged in smoking
cessation treatment. Our results indicate that there is a number of barriers to the provision of effective smoking cessation treatment
in patients with chronic obstructive pulmonary disease and smokers in general. Introducing an informative smoking cessation
programme, including communication skills and ethical issues, in the vocational and postgraduate medical training may help to
address these barriers. This is important in order to increase engagement with smoking cessation treatment and to improve quality
of chronic obstructive pulmonary disease care.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major public
and individual health problem. Experts think that, by 2020, COPD
will rank ﬁfth worldwide in terms of burden of disease and third in
terms of mortality.1 Higher mortality rates and an accelerated
decline in lung function are seen in patients with COPD who
continue smoking.1 Smoking cessation is therefore the most
important treatment for patients with COPD, as it is the only
evidence-based intervention which has been proven to slow
down the accelerated decline in lung function.1
To promote smoking cessation, international COPD guidelines
include recommendations for effective smoking cessation inter-
ventions.1, 2 They state, in accordance with the Cochrane review
on smoking cessation in patients with COPD, that a combination
of behavioural and pharmacological interventions is superior to
any other treatment.3 Nevertheless, the prevalence of smoking in
patients with COPD is still high and there is evidence that it
exceeds the rate of smoking in the general population.4 There is
only limited evidence that patients get motivated to quit on
receiving a diagnosis of COPD.5 This implies that many COPD
patients still continue smoking even though quitting is their best
treatment option.
Physicians play a very important role in providing effective
smoking cessation treatment for these patients. However,
literature shows that they do not routinely deal with smoking
cessation during their consultations with smokers.6–8 According to
a large European review, several factors seem to inﬂuence
physicians’ engagement in smoking cessation: patient character-
istics; physician-characteristics, including attitude and cessation-
speciﬁc knowledge and skills; structural factors, including reim-
bursement and time required.8 A different review found that some
physicians had negative thoughts about smoking cessation
treatment as they considered it time-consuming and ineffective,
and they lacked conﬁdence in their ability to discuss smoking
cessation with their patients.9
To our knowledge, no attention has been given in the literature
speciﬁcally to physicians’ views on smoking cessation treatment
for smokers with COPD. Whereas, for this group of smokers, it is
more urgent that they quit smoking, while it is even more difﬁcult
due to their higher addiction levels and higher susceptibility to
developing depressive symptoms.10–12 There are studies exploring
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experiences with COPD care in general, but these studies do not
speciﬁcally address smoking cessation.13–16 From these studies, it
is apparent that engagement in COPD care is inﬂuenced by
physician-related factors such as perceived low self-efﬁcacy in the
provision of treatment and lack of conﬁdence in the effects of
treatments.13, 16 Also, patient-related factors such as being non-
compliant and not taking responsibility for their condition were
barriers for carrying out COPD care.15 Furthermore, awareness of
available treatments and support for patients with COPD, as well
as the time required for such treatments seemed to create
organisational barriers.14 It is not clear whether these factors also
hinder smoking cessation care in patients with COPD or if there
are different issues in this speciﬁc population.
The aim of this study was therefore to explore how physicians
engage in smoking cessation treatment for their COPD patients, by
exploring their attitudes, reported practice and experienced
problems in this regard. Once researchers and physicians understand
speciﬁc needs and concerns regarding utilising cessation treatments
for this particular group of smokers, they may address these
problems in order to increase smoking cessation in COPD patients.
RESULTS
Physicians’ frustration with COPD patients who smoke
Many physicians shared negative feelings towards patients with
COPD who continued smoking. This seems to hinder them in
providing evidence-based treatment, including smoking cessation
treatment.
Physicians seemed to feel responsible for motivating patients to
quit smoking.
‘Yes, make them, make them to wish to stop smoking (laughs a
bit) is what we should do.’ [FGD 1, Norway, GP]
Several discussions focused on how exhausting it is for
physicians to spend their valuable time on COPD patients and
to prescribe expensive medication to relieve symptoms. Never-
theless, many physicians seemed to conﬂate the importance of
supporting patients to quit smoking with a personal desire to try
and make them stop. They reported frustration regarding patients
who demanded treatment but refused to accept responsibility for
the treatment themselves.
‘They [COPD patients that smoke] are a very difﬁcult patient
group, especially those that are just on the cusp of needing
long term oxygen and you’re trying to convince them that
you’re not going to give it to them if they don’t stop smoking
… it’s very frustrating if they still persist…’ [FGD 3, Wales,
Pulmonologist]
Other frustrations that hindered physicians in working with
smokers with COPD were difﬁculties in communication. Physicians
reported that some patients no longer attended surgery because
they do not like hearing about smoking cessation or feel guilty
about their smoking behaviour.
‘It’s difﬁcult to treat and handle this group of patients, right?
You need to strongly motivate them in order to [make them
stop smoking] … if you press them too much you will reject
them; if you press them too hard to make them stop smoking
you will make them your enemies: that’s the ﬁne line.’ [FGD 1,
Norway, GP]
Some also believed patients were ‘lying’ about their smoking
behaviour. Others reported that COPD patients, when questioned
about their smoking behaviour, consciously or unconsciously,
trivialized their smoking behaviour.
‘I switched to ‘light’ cigarettes’ and, ‘Doctor, I’ve quit! I have not
smoked for three days!’ He smoked for 50 years before’. [FGD 2,
Russia, pulmonologists]
Eventually, all these frustrations resulted in a general feeling of
dissatisfaction with regards to supporting COPD patients with
quitting smoking.
‘…it is almost like tilting against windmills.’ [FGD 3, Poland,
pulmonologist]
These negative experiences with smokers with COPD seemed to
contribute to physicians being prejudiced against smokers with
COPD. Some physicians discussed the issue that these prejudge-
ments provoke the risk of treating smokers with COPD differently.
Some said that they found smokers with COPD ‘nonsensical’ and it
was their own fault they had COPD, and were more reluctant to
prescribe expensive medication. Another physician said that if a
COPD patient had quit smoking ‘he has a plus in our view and we
should take care of him’ [FGD 1, Poland, GP].
In conclusion, these physicians felt responsible for ‘making’
COPD patients quit smoking. However, they experienced many
patient-related barriers which frustrated them. These frustrations
provoked the risk of developing negative feelings about this
group of patients, and subsequently treating them unequally and
potentially depriving them of the most effective treatments.
Physicians’ limited knowledge of, and negative beliefs about,
smoking cessation treatment
Many of the physicians felt they lacked experience and conﬁdence
in helping patients to stop smoking. Some also questioned the
effectiveness of smoking cessation treatments. In the discussion of
this, the physicians seemed inclined to switch from COPD-speciﬁc
topics to topics regarding the general smoking population.
Even though all the physicians emphasised that smoking
cessation is the most essential treatment for smokers with COPD,
some of them questioned whether this also applied to particular
groups of patients, e.g., late stages of COPD.
‘No, it has been proven that if you do not smoke you are better
off; if you quit at a young age you are better off… but those
people who are at a certain stage of COPD …those data are
not convincing.’ [FGD 3, Netherlands, pulmonologist] (There
are studies that show that also smokers in severe and very
severe stages of COPD beneﬁt from quitting smoking in terms
of their quality of life and lung function17, 18)
Physicians from the Netherlands, Germany and Norway
expressed the view that there were COPD patients who did not
necessarily feel better after quitting smoking. It was difﬁcult for
them to explain the beneﬁts of quitting to their patients without
the prospect of a positive result.
Furthermore, several physicians stated that they were inexper-
ienced in providing smoking cessation treatment. They reported
ﬁnding it hard to talk to patients about smoking habits, regarding
it as a delicate subject. They would also like to have tools for the
promotion of smoking cessation, such as tools for communication
and patient education. This was one of the topics of discussion
about smoking cessation in general and not only about smokers
with COPD.
‘We need resources on creating an atmosphere and educating
patients…in order to increase their motivation to quit smoking
and increase the success rate…’ [FGD 3, Hong Kong, GP]
Besides Hong-Kong, Norway and Russia in particular brought up
this issue. In Russia, they also discussed the effectiveness of
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pharmacotherapy in the general smoking population. In Germany,
there seemed to be a lack of trust in nicotine replacement therapy
(NRT). Physicians in both Russia and Germany discussed the view
that these aids would only delay quitting and not cure these
patients (NRT has been proven to improve long-term abstinence
from tobacco19). In addition, smoking cessation medication was
said to be very expensive and therefore not widely used. In
Germany, the physicians concluded that the most important
element in smoking cessation is the communication with the
patient.
‘And the communicative intervention, so to say, is more
successful [in motivating quitting] than, for instance, a nicotine
patch.’ [FGD 3, Germany, pulmonologist]
Besides these general discussions, there were some conversa-
tions that focussed more on smokers with COPD. The tenor of
these discussions was speculative about communication, educa-
tional and social tools for motivating COPD patients to quit. For
example, some physicians thought it might help to dramatise and
scare the patient and they would like to have tools to illustrate the
harm smoking does to your lungs (Confronting smokers with
undetected COPD in a randomised controlled trial did not increase
the rate of smoking cessation20; however, in a recent cohort study,
a new diagnosis of COPD seemed to be linked to smoking
cessation5). Furthermore, social inﬂuences were discussed as
motivational tool: for example, a story was told about a grand-
father who quit smoking when his granddaughter said he was not
allowed to die yet.
Healthcare organisational factors that inﬂuence the use of
smoking cessation treatments
In this theme, the inﬂuence of health care organisational factors
on smoking cessation treatment is discussed. In these discussions,
the physicians broadened their views to include issues related to
smoking cessation in general.
Smoking cessation treatment, in most countries, did not appear
to be common practice in COPD care. Physicians from the
Netherlands, Wales, Germany and Hong Kong reported lack of
time and ﬁnancial reimbursement as important obstacles for
providing smoking cessation treatment.
‘It [quitting smoking] is part of the questionnaire, it is one of
the items on the list you need to cover… but it is so time-
consuming.’ [FGD 1, Netherlands, GP]
The physicians in the Netherlands felt there was not sufﬁcient
time in the COPD check-up appointment to discuss smoking
cessation. In Germany, they grumbled about the price/quality ratio
of the existing smoking cessation treatments.
‘It’s not economical but you shouldn’t lose your enthusiasm
there.’ [FGD 3, Germany, pulmonologist]
The time spent on smoking cessation treatments is not
recovered, as only a few people eventually quit smoking. In
Russia and Germany, they discussed the importance of how
smokers are ‘labelled’. This was not a COPD-speciﬁc discussion but
concerned all smokers.
‘I consider that for some people, smoking is a disease, the same
as alcohol dependency, for example.’ [FGD 3, Russia, GP]
In line with this, they discussed the availability and reimburse-
ment of facilities for smoking cessation and compared it to
facilities for other addictions in Germany.
‘Every alcoholic receives a detox, but a nicotine patient has to
pay for his addiction himself. And this isn’t fair as both are
partly recognised as addictions.’ [FGD 3, Germany, GP]
Apparently, in some countries, insurance companies and other
important institutions in healthcare organisation consider smok-
ing addiction to be different from other addictions. They do not
provide the same facilities for smokers as for other addicted
patients, such as alcoholics, whilst smoking is ofﬁcially recognised
as a drug-related illness by addiction treatment care.
DISCUSSION
Main ﬁndings
In the focus group discussions (FGDs), the physicians mentioned
patient-related, physician-related and healthcare organisational
factors that hindered the routine provision of evidence-based
smoking cessation treatment to patients with COPD. Some of the
issues were not speciﬁc for smokers with COPD, but concerned
smokers in general. Firstly, physicians experienced great frustra-
tion regarding smokers with COPD. In their view, smokers with
COPD tended not to accept responsibility for their treatment;
often were not honest about their smoking habits; trivialized the
consequences of smoking and avoided health care visits. These
frustrations provoked the risk of developing negative feelings
about this group of patients, and treating them unequally by
depriving them of effective treatments. Secondly, physicians
lacked experience with different smoking cessation treatments.
Thirdly, money and time issues, but also the failure to regard
smoking as a disease, inﬂuenced physicians’ treatment of smokers
with COPD and also smokers in general.
Interpretation of ﬁndings in relation to previously published work
Physicians experienced frustration when working with smokers
with COPD, as these patients were perceived as not taking
responsibility for their disease. Present societal norms emphasise
personal responsibility for one’s health21 and physicians expect
their patients to act in the interest of successful health
maintenance.22 Smokers with COPD fall short of these expecta-
tions as their disease has been caused by their own smoking
behaviour, and many do not act to stop the progression of their
disease by quitting. In this societal context, smokers with COPD
feel stigmatised and they might be hesitant to contact their
physicians because they fear criticism21 and become irritated by
their advice to stop smoking.23 However, research shows the vast
majority of smokers are happy for their physician to raise the topic
of smoking, if the advice is given in an empathetic and patient-
centred manner.23–25 In order to create an environment with less
frustration, it is important that physicians contribute to reducing
the negative effect of stigma,21 as this interferes with the
physician-patient relationship. In our view, some physicians need
to develop a less paternalistic style, and create room for the
smokers’ own views.12, 21
Many physicians reported limited knowledge, conﬁdence and
skills regarding evidence-based smoking cessation treatments. A
Europe-wide literature review demonstrated that the proportion
of GPs that offer intensive smoking cessation interventions is low
and that one of the reasons for this was limited knowledge and
skills.8 This is conﬁrmed by studies examining risk factor
management and COPD management in general.14, 26 In national
and international guidelines, there are overviews of the different
effective smoking cessation options,27, 28 but literature has shown
that physicians are not always familiar with these guidelines.13
Several factors can inﬂuence physicians’ adherence to guidelines,
such as physicians’ view of their role in COPD care and how
complex certain care is.14 In this study, we have seen that many
physicians do not have faith in the guideline recommendations.
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Besides, the physicians mentioned that they thought commu-
nication was more important than prescribing pharmacotherapy
and that it is difﬁcult to familiarise oneself with communicative
tools via theory. In order to increase skills and knowledge, it seems
important to provide a smoking cessation programme in
vocational training and postgraduate smoking cessation training
for GPs. In this training, physicians should be taught evidence-
based smoking cessation treatment and practise communication,
besides reﬂection on personal norms and values.
Healthcare organisational factors inﬂuence how physicians
engage in COPD care and smoking cessation. Each of the seven
countries involved in this study organises COPD care in a different
way. The Netherlands,29 Germany,30 Wales31 and Norway32 have
the most structured COPD care. In Poland,33 Russia and Hong-
Kong, the disease management programs seem to be less
established. Even with structured care, however, there are several
issues that complicate providing evidence-based smoking cessa-
tion treatment. Lack of time is often mentioned in the literature as
a barrier to giving smoking cessation treatment.8, 9 In this study,
the physicians further complained that the ﬁnancial reward is
insufﬁcient. To our knowledge, there are no studies on the
differences in outcomes when comparing the different healthcare
systems. We can, however, see that in the Netherlands, Germany,
Wales, Norway and Poland, the smoking rate is between
20–26%.34 In Russia, this number is much higher: 37.3% of people
over 15 years of age smoke.34 In China, almost 50% of men smoke,
but almost no women.34 It would be interesting to know if the way
the healthcare system is organised inﬂuences smoking cessation,
especially for smokers with COPD who, even at the best of times,
experience difﬁculties in quitting.35
As smoking is ofﬁcially recognised as an illness in addiction
treatment care, it is interesting to note that in none of the
countries rehabilitation programs for smoking are offered in the
same way as rehabilitation from other drugs. This shows that there
is still a stigma attached to smoking that considers it to be
different from other addictions. If smoking is seen as an addiction
such as with other drug addictions, then structured nicotine
dishabituation programmes might be established and reimbursed.
Strengths and limitations of this study
The primary dataset that we used was extensive, therefore the
strength of this study is to be found in the participation of several
countries in order to ﬁnd common concerns regarding smoking
cessation in different healthcare settings. We did not aim for a
comparative study as a strict comparison between countries could
not be made due to the plethora of information and scattered
quotes on smoking. Furthermore, both GPs and pulmonologists
attended the FGDs. This gave a fuller picture of physicians’
concerns regarding smoking cessation. In theme three, we brieﬂy
mention the importance of the different healthcare contexts for
the interpretation and analysis of the information. A weakness in
this study is that we were not able to specify exactly what role the
different health contexts played for the construction of the
concerns. Analysis of the data was done together with two
researchers that participated in the primary data collection and
analysis, and was proof read by all representatives from the
different countries that participated. One other limitation is that
the FGDs were originally designed to explore GPs’ and pulmonol-
ogists’ views and concerns on the management of COPD
exacerbations in general. Smoking cessation is, of course, very
important herein, but was not the main focus of the FGDs. On the
other hand, this concomitantly resulted in important gut reactions
on smoking related issues. This means that the results are
reﬂections of most discussed concerns and we see them as
hypothesis generating for future in-depth research in this ﬁeld.
Implications for future research, policy and practice
To promote physicians’ engagement in smoking cessation
treatment, we advise introducing an informative smoking cessa-
tion programme, including communication and ethic, into the
vocational training and postgraduate medical training. The
attachment of stigma should be considered in this training and
how this interferes with giving professional smoking cessation
support. In addition evidence-based smoking cessation treatment
should be taught and communication should be practiced. For
future research, it would be interesting to take a more detailed
look into the hypothesis generating results of this analysis
including the inﬂuence of different healthcare systems on how
smoking cessation treatment is performed. This will inform us
about which elements are essential for performing effective
smoking cessation treatment.
CONCLUSIONS
Our results show physicians’ barriers to providing effective
smoking cessation treatment in patients with COPD and smokers
in general. This is inﬂuenced by general issues and attitudes
regarding smoking cessation treatment and the management of
patients with COPD. We saw a lot of frustration, inexperience and
stigmatisation in physicians regarding smoking cessation in their
COPD patients and in the general smoking population. Also,
money and time issues hindered the physicians. It is important to
increase engagement with smoking cessation treatment and
thereby improve quality of COPD care.
METHODS
Data collection
We used FGDs to explore how physicians comment on their engagement
in smoking cessation treatment for COPD patients. A FGD design was
found suitable as FGDs serve to create data within a group setting, and we
wished to take advantage of the different inputs from physicians and their
co-construction of meaning, rather than relying on individual interview
data. Further, FGDs have the potential to bring forth and discuss different
spontaneous viewpoints in relatively understudied domains, such as this
domain.36, 37 We performed a secondary analysis together with researchers
who had held the FGDs for the primary research. The FGDs were held in
seven different countries in 2011–2012: Wales, the Netherlands, Poland,
Russia, Germany, Norway and Hong Kong. These countries were selected
due to earlier research collaboration on respiratory diseases. The FGDs
were originally designed to explore general practitioners’ (GPs) and
pulmonologists’ views and concerns on the management of COPD
exacerbations in general.15, 38
Each country performed three FGDs with 4–7 participants considering
that the chosen participants and the number of FGDs would provide
sufﬁcient information to answer the original study questions. The number
of participants in each FGD should ideally be between 6–8 as often
recommended,39 but due to cancellations the number differed in the end.
For each FGD new participants were recruited: FGD 1 with only GPs; FGD 2
with only pulmonologists; FGD 3 with a mix of GPs and pulmonologists. In
FGD 1 and 2, GPs and pulmonologists got the chance to discuss issues
from the viewpoint of their discipline without being interfered by the other
discipline. In FGD 3 these issues could then be combined in an
interdisciplinary discussion. The GPs and pulmonologists were sampled
in order to cover both rural and urban GP practices, as well as private-
based and hospital-based pulmonologists.15, 38
All researchers who were responsible for conducting the FGDs
participated in a 3-day workshop in order to streamline the methods
across countries. All countries used the same interview guide containing
topics based on known issues of concern to GPs. The interview guide used
in FGD 1 was revised before FGD 2 due to intermediary analysis and this
revised version with speciﬁc sub questions was used in FGD 2. The
pulmonologists were asked to discuss the routines in general practice as
they were known to them, but inviting them to be open about their own
views and concerns. Between FGD 2 and 3 another revision of the
interview guide was made in order to make FGD 3 focus especially on
topics that were still unclear but also on solutions to identiﬁed problems.
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All FGDs were transcribed verbatim from audio recording by the local
researchers and translated into English by a skilled translator. However,
some inconsistencies in English language occurred and we show adjusted
quotes in the results section with the original quotes in the attachment.
For this analysis, the focus group transcripts were imported into Nvivo 10.
Data assessment
To address the additional research question for this secondary analysis, we
assessed the quality of the available dataset and discussed whether the
existing dataset had the potential to inform us about physicians’
engagement in smoking cessation. All transcripts were reviewed by E.E.
in order to discover whether they were relevant for this secondary analysis.
This was then discussed within the research team (M.B.R., M.S., D.K.) and it
was agreed that the dataset as a whole offered rich data on physicians’
engagement in smoking cessation. Most of the data for the secondary
analysis arose from questions in all FGDs about difﬁcult COPD patients.
FGD 1 and 2 included a question asking, ‘Could you describe speciﬁcally
challenging or difﬁcult clinical situations with COPD-patients in general? ’
FGD 3 included a question asking, ‘Who are the difﬁcult patients and how
do you reach them? What do you think are the key issues/bottlenecks
regarding the difﬁcult patients? ’ These questions led to discussions about
smoking and smoking cessation in COPD patients. Furthermore, we found
valuable information in discussions on challenges when coping with
patients with COPD; how to improve care and own views and concerns.
Also, sections in which exacerbation management, self-management and
guidelines were discussed provided interesting information. Information
from FGD 3 contributed the most to this secondary analysis.
Analysis
The available data were then analysed using an inductive thematic
analysis40 and we coded the text without initially relating it to the aim of
the study. As there were no predeﬁned categories, this enabled the
evolution of different categories through the coding process. E.E.
formulated codes for all text that was linked to smoking and smoking
cessation. Codes were then discussed in detail and sorted into categories
and subcategories (E.E., M.B.R.). For example, ‘patients not open to
physicians’ smoking cessation advice’ was a subcategory of ‘patients who
do not quit’. The codes were then discussed within the research team (M.B.
R., M.S., D.K.) and the essential contents of the codes were divided into
three candidate themes related to the overall aim. Simultaneously, the ﬁnal
aim of the study was discussed within the team (O.V.S., M.B.R.) and the
themes could then be ﬁnalised. This process resulted in three themes: (1)
‘physicians’ frustration with COPD patients who smoke’; (2) ‘physicians’
limited knowledge of, and negative beliefs about, smoking cessation
treatment’; (3) ‘healthcare organisational factors that inﬂuence the use of
smoking cessation treatments’. E.E. checked to ensure that the resulting
thematic map accurately reﬂected the meaning of units evident in the
dataset as a whole.40
Ethical considerations
Methods were performed in accordance with relevant regulations and
guidelines. Relevant ethical approval was obtained from the appropriate
bodies in the participating countries; South East Wales Research Ethics
Committee Panel (Wales), Medical Ethical Review Committee of University
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mittee of Northern State Medical University (Russia). Participants provided
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